<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158925</url>
  </required_header>
  <id_info>
    <org_study_id>Clinicals0001</org_study_id>
    <nct_id>NCT00158925</nct_id>
  </id_info>
  <brief_title>The EASYTRAK EPI Clinical Investigation</brief_title>
  <acronym>EASYTRAK EPI</acronym>
  <official_title>The EASYTRAK EPI Clinical Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of the EASYTRAK EPI lead.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-armed, multi-center U.S., Australian, Canadian, and European
      clinical investigation, designed to demonstrate the safety and effectiveness of the EASYTRAK
      EPI lead in humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic Pacing Thresholds at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The expected mean pacing threshold is 1.9V at 0.5 ms pulse width.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chronic Pacing Impedances at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The expected mean impedance is 500 Ohms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chronic Sensing Amplitudes at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The expected mean is 10mV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lead-related Complication-free Rate at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The estimated target value for this endpoint is 80%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lead Implant Time</measure>
    <time_frame>Implant</time_frame>
    <description>The estimated target value for average implant time is 30 minutes. Unit of measure will be the time period needed for the implant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Bradycardia</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>EASYTRAK EPI Lead</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will be implanted or attempted with the EASYTRAK EPI lead.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EASYTRAK EPI lead</intervention_name>
    <description>EASYTRAK EPI lead</description>
    <arm_group_label>EASYTRAK EPI Lead</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet the EASYTRAK EPI indications

          -  Patients who are age 18 or above, or of legal age to give informed consent specific to
             state and national law

          -  Patients who are willing and capable of providing informed consent, undergoing a
             device implant, participating in all testing associated with this clinical
             investigation at an approved clinical investigational center and at the intervals
             defined by this protocol

          -  Patients who meet any one of the following three conditions:

               -  Meet current indications for cardiac resynchronization therapy (CRT) and
                  epicardial placement of a pace/sense lead on the left ventricle is preferred over
                  an endocardial lead

               -  Meet current indications for a cardiac pacing system and have documented evidence
                  that an endocardial lead cannot be used

               -  Meet current indications for a cardiac pacing system and a concurrent cardiac
                  surgical procedure is taking place where no additional surgical procedures are
                  required to provide access to the epicardial surface of the heart

        Exclusion Criteria:

          -  Patients who meet the EASYTRAK EPI contraindications

          -  Patients who have had a myocardial infarct, unstable angina, or percutaneous coronary
             intervention during the preceding 30 days prior to enrollment

          -  Patients with a documented life expectancy of less than 6 months or expected to
             undergo heart transplant within the next 6 months

          -  Patients enrolled in any concurrent study, without Guidant written approval, that may
             confound the results of this study

          -  Women who are pregnant or plan to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Beckman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multiple Locations in the US</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>March 17, 2017</results_first_submitted>
  <results_first_submitted_qc>March 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2017</results_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Artificial Cardiac Pacing</keyword>
  <keyword>Implanted Electrodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EASYTRAK EPI Implant Group</title>
          <description>This is a single arm study, all study subjects are to be implanted in 1 arm: the EASYTRAK EPI Implant Group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96">96 subjects were implanted or attempted with the study lead</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EASYTRAK EPI Lead</title>
          <description>Subjects in this arm will be implanted or attempted with the EASYTRAK EPI lead.
EASYTRAK EPI lead: EASYTRAK EPI lead</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.1" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Chronic Pacing Thresholds at 3 Months</title>
        <description>The expected mean pacing threshold is 1.9V at 0.5 ms pulse width.</description>
        <time_frame>3 months</time_frame>
        <population>Although 96 subjects were implanted/attempted, for 80 subjects still in follow up at the end of the 3M fu periodm the mean pacing threshold was obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>EASYTRAK EPI Implant Group</title>
            <description>This is a single arm study, all study subjects are to be implanted in 1 arm: the EASYTRAK EPI Implant Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Pacing Thresholds at 3 Months</title>
          <description>The expected mean pacing threshold is 1.9V at 0.5 ms pulse width.</description>
          <population>Although 96 subjects were implanted/attempted, for 80 subjects still in follow up at the end of the 3M fu periodm the mean pacing threshold was obtained.</population>
          <units>V</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chronic Pacing Impedances at 3 Months</title>
        <description>The expected mean impedance is 500 Ohms.</description>
        <time_frame>3 months</time_frame>
        <population>Although 96 subjects were implanted/attempted, for 80 subjects still in follow up at the end of the 3M fu period, the mean impedance was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>EASYTRAK EPI Implant Group</title>
            <description>This is a single arm study, all study subjects are to be implanted in 1 arm: the EASYTRAK EPI Implant Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Pacing Impedances at 3 Months</title>
          <description>The expected mean impedance is 500 Ohms.</description>
          <population>Although 96 subjects were implanted/attempted, for 80 subjects still in follow up at the end of the 3M fu period, the mean impedance was measured.</population>
          <units>Ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500" spread="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chronic Sensing Amplitudes at 3 Months</title>
        <description>The expected mean is 10mV.</description>
        <time_frame>3 months</time_frame>
        <population>Although 96 subjects were implanted/attempted, for 67 subjects still in follow up at the end of the 3M fu period, chronic sensing amplitude was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>EASYTRAK EPI Implant Group</title>
            <description>This is a single arm study, all study subjects are to be implanted in 1 arm: the EASYTRAK EPI Implant Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Sensing Amplitudes at 3 Months</title>
          <description>The expected mean is 10mV.</description>
          <population>Although 96 subjects were implanted/attempted, for 67 subjects still in follow up at the end of the 3M fu period, chronic sensing amplitude was measured.</population>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lead-related Complication-free Rate at 3 Months</title>
        <description>The estimated target value for this endpoint is 80%.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EASYTRAK EPI Implant Group</title>
            <description>This is a single arm study, all study subjects are to be implanted in 1 arm: the EASYTRAK EPI Implant Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Lead-related Complication-free Rate at 3 Months</title>
          <description>The estimated target value for this endpoint is 80%.</description>
          <units>% of complication free-rate</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="95.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lead Implant Time</title>
        <description>The estimated target value for average implant time is 30 minutes. Unit of measure will be the time period needed for the implant.</description>
        <time_frame>Implant</time_frame>
        <population>Although 96 subjects were implanted/attempted, lead implant time was only collected for 69 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>EASYTRAK EPI Implant Group</title>
            <description>This is a single arm study, all study subjects are to be implanted in 1 arm: the EASYTRAK EPI Implant Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Lead Implant Time</title>
          <description>The estimated target value for average implant time is 30 minutes. Unit of measure will be the time period needed for the implant.</description>
          <population>Although 96 subjects were implanted/attempted, lead implant time was only collected for 69 subjects.</population>
          <units>h.min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EASYTRAK EPI Implant Group</title>
          <description>This is a single arm study, all study subjects are to be implanted in 1 arm: the EASYTRAK EPI Implant Group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Abnormal lab values</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Distal thromboemboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Unable to capture-LV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Impedance&gt;2000 Ohms LV lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Dislodgment-no reported signs-LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Dislodgment-multiple signs-LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Dislodgment-Unable to capture-LV</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation-RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Inadvertent VT/VF</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Low cardiac output</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms-unspecified</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Impedance &gt; 2000 Ohms-RV lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Unable to capture- non RA lead related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Chest pain-ischemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Multi-system failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated blood glucose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General adverse reaction</sub_title>
                <description>These adverse events were monitored/assessed without regard to the specific Adverse Event Term.</description>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (&gt;30 days post implant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Post-surgical infection (&lt;30 days post-implant)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Phrenic nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Post-up urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax-procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pleuritic chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Atelactasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pulmonary symtpoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma-pocket</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Post-surgical wound-discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dehiscence of incision over PG</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage-procedural related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Thromboembolic events</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Vasovagal symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation-LV lead</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Inappropriate tachy therapy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General adverse event</sub_title>
                <description>Adverse events were monitored/assessed without regard to the specific Adverse Event Term.</description>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary adverse events</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Post-surgical wound discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elke Sommerijns</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>+32 479 76 71 56</phone>
      <email>elke.sommerijns@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

